Kaisa Laapas

R&d
Turku, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.

Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.

Journal: Maturitas

Published: April 15, 2026

Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial.

Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial.

Journal: Journal of clinical medicine

Published: January 15, 2026

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Journal: JAMA internal medicine

Published: September 08, 2025

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.

Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.

Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.

Journal: F&S science

Published: April 21, 2023

Utilization of anonymization techniques to create an external control arm for clinical trial data.

Utilization of anonymization techniques to create an external control arm for clinical trial data.

Journal: BMC medical research methodology

Published: March 23, 2023

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.

Journal: The Lancet. Rheumatology

Published: March 17, 2023

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.

Journal: Annals of the rheumatic diseases

Published: December 13, 2019

Dexmedetomidine oromucosal gel for noise-associated acute anxiety and fear in dogs-a randomised, double-blind, placebo-controlled clinical study.

Dexmedetomidine oromucosal gel for noise-associated acute anxiety and fear in dogs-a randomised, double-blind, placebo-controlled clinical study.

Journal: The Veterinary record

Published: January 22, 2017

Showing 1-9 of 9

Last Updated: 09/26/2026